Mrm Health

Mrm Health company information, Employees & Contact Information

Explore related pages

Related company profiles:

MRM Health NV is a biopharmaceutical company focused on the discovery and development of innovative therapeutics based on the human microbiome.The company is based in a Center of Expertise for microbiome research and development in the biotech cluster in Ghent, Belgium, and has a strategic partnership with the VIB, with top research groups in both microbiome analysis and ecology and in host biology and disease research. The Company is strategically supported by strong local and international investors, including Ackermans & van Haaren, DuPont, MRM Technologies, Qbic II and VIB and has a corporate collaboration with DuPont Nutrition Biosciences in the development of microbiome-based therapeutics for metabolic diseases. MRM Health's proprietary technology platform brings live microbial therapeutics development to the next level by combining rationally selected strains into synergistic consortia through a proprietary optimization process.

Company Details

Employees
42
Founded
-
Address
Technologiepark-Zwijnaarde 94, Ghent,flemish Region 9052,belgium
Phone
+32 9 241 11 88
Email
in****@****lth.com
Industry
Biotechnology
HQ
Ghent, Flemish Region
Looking for a particular Mrm Health employee's phone or email?

Mrm Health Questions

News

MRM Health Raises €55 Million Series B to Advance Best-in-Class Microbiome-Based Biotherapeutic Product Pipeline - Business Wire

MRM Health Raises €55 Million Series B to Advance Best-in-Class Microbiome-Based Biotherapeutic Product Pipeline Business Wire

MRM Health secures $64m for microbiome-based pipeline - Pharmaceutical Technology

MRM Health secures $64m for microbiome-based pipeline Pharmaceutical Technology

Belgium's MRM Health raises €55 million for microbiome-based biotherapeutic product pipeline - EU-Startups

Belgium's MRM Health raises €55 million for microbiome-based biotherapeutic product pipeline EU-Startups

MRM Health Secures €55 Million in Series B Financing to Propel Microbiome-Based Therapeutics - SynBioBeta

MRM Health Secures €55 Million in Series B Financing to Propel Microbiome-Based Therapeutics SynBioBeta

Microbiome play MRM Health NV raises €55m in Series B - European Biotechnology Magazine

Microbiome play MRM Health NV raises €55m in Series B European Biotechnology Magazine

MRM Health Closes $64M Series B Financing Round - Contract Pharma

MRM Health Closes $64M Series B Financing Round Contract Pharma

Microbiome startup MRM Health nabs €55M Series B to run Phase 2b ulcerative colitis trial - Endpoints News

Microbiome startup MRM Health nabs €55M Series B to run Phase 2b ulcerative colitis trial Endpoints News

MRM Health secures €55m to advance microbiome-based therapeutics - World Pharmaceutical Frontiers

MRM Health secures €55m to advance microbiome-based therapeutics World Pharmaceutical Frontiers

Ghent’s MRM Health raises €55M to accelerate clinical development of next-gen microbiome drugs - Tech Funding News

Ghent’s MRM Health raises €55M to accelerate clinical development of next-gen microbiome drugs Tech Funding News

Best-in-Class Experimental Gut Bacteria-Based Medicine: MRM Health Lands US$64 Million Series B - geneonline.com

Best-in-Class Experimental Gut Bacteria-Based Medicine: MRM Health Lands US$64 Million Series B geneonline.com

MRM Health Raises €55M Series B Funding - FinSMEs

MRM Health Raises €55M Series B Funding FinSMEs

MRM Health Appoints Grégoire Franoux as Chief Business Officer and Adds Ron Robison to its Board of Directors - Business Wire

MRM Health Appoints Grégoire Franoux as Chief Business Officer and Adds Ron Robison to its Board of Directors Business Wire

MRM Health reports data from ulcerative colitis therapy trial - Clinical Trials Arena

MRM Health reports data from ulcerative colitis therapy trial Clinical Trials Arena

Biocodex Invests up to €30 Million in MRM Health, a Belgian Microbiome Therapy Innovator - Business Wire

Biocodex Invests up to €30 Million in MRM Health, a Belgian Microbiome Therapy Innovator Business Wire

MRM Health Reports Positive Topline Results from Phase 2a Clinical Study with MH002 in Mild-to-Moderate Ulcerative Colitis - Via TT

MRM Health Reports Positive Topline Results from Phase 2a Clinical Study with MH002 in Mild-to-Moderate Ulcerative Colitis Via TT

Top Mrm Health Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant